Spirulina and Prostaglandin E2

PGE2 Synthesis: COX-1, COX-2, mPGES

Arachidonic acid is converted to PGH2 by COX-1 (constitutive) or COX-2 (inducible), then to PGE2 by three PGE synthases: cytosolic cPGES (constitutive), membrane-bound mPGES-1 (inducible by inflammation, paired with COX-2), and mPGES-2 (constitutive). mPGES-1 is the dominant PGE2 source in inflammation and the rate-limiting step. mPGES-1 inhibitors are in development as next-generation NSAIDs without cardiovascular toxicity.

EP1-EP4 Receptor Diversity

PGE2 acts through four GPCRs with distinct signaling. EP1 (Gq, calcium, hyperalgesia); EP2 (Gs, cAMP, immunosuppression, anti-fibrosis in lung); EP3 (Gi, fever induction, platelet inhibition); EP4 (Gs, cAMP, macrophage M2 polarization, resolution). Selective modulation of EP receptors yields different therapeutic profiles.

Phycocyanin Selectively Suppresses COX-2

Phycocyanin inhibits COX-2 with greater selectivity than COX-1, by approximately 10-fold preference in enzyme assays. This is favorable: COX-1 inhibition causes gastric and renal side effects; COX-2 inhibition addresses inflammation. The selectivity differs from celecoxib (designed COX-2 selective) but achieves similar ratio empirically. Net PGE2 reduction in inflammation: 25–40%.

Cardiovascular Safety

Selective COX-2 inhibition (rofecoxib, valdecoxib) increased cardiovascular events via reduced prostacyclin (PGI2) without affecting platelet TxA2. Phycocyanin's COX-2 selectivity is less complete than pharmacologic inhibitors, and combined with GLA-driven DGLA shift (reducing AA pool for both COX-1 and COX-2), avoids the prostacyclin-TxA2 imbalance. Clinical CV signals with high-dose spirulina: none.

PGE2 in Pain vs Resolution

Acute pain involves EP1-mediated hyperalgesia. Phycocyanin's PGE2 reduction provides analgesic effects in inflammatory pain models comparable to low-dose ibuprofen. However, late-phase PGE2 via EP4 drives macrophage M2 polarization and resolution. Spirulina's broader anti-inflammatory effects (NF-κB, NLRP3 covered elsewhere) compensate for any blunted resolution-phase PGE2 — net pro-resolution.

Conclusion

Spirulina's effects on PGE2 axis include selective COX-2 inhibition (~10-fold preference), GLA-DGLA-mediated reduction in arachidonic acid substrate pool, and mPGES-1 expression reduction via NF-κB suppression. Net PGE2 reduction (25–40%) is balanced by enhanced resolution from broader anti-inflammatory mechanisms. Clinical correlates: modest analgesic effects in chronic inflammatory pain, reduced fever in febrile illness, and improved inflammation resolution without the cardiovascular signal of selective pharmacologic COX-2 inhibition.